Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Rheumatol ; 39(1): 263-268, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31346886

RESUMO

To evaluate the drug treatment trends in patients with incident juvenile idiopathic arthritis (JIA) in 2006-2014. In Finland, patients are entitled to a special reimbursement for medication if their condition meets certain criteria. We gathered all reimbursement decisions with the ICD-10 diagnosis of M08 for patients under 16 years of age from a nationwide register maintained by Kela, the Social Institution of Finland. A total of 2439 incident cases of JIA were identified. We surveyed their reimbursable drugs purchased for the first time for JIA upon a doctor's prescription in 3-year cohorts (2006-2008, 2009-2011, 2012-2014). Changes of drug treatment for JIA became more active during our study years. Between 2006-2008 and 2011-2014, the introduction of methotrexate (MTX) for the first time within the first 3 months increased from 73% (2006-2008) to 90% (2011-2014) of the patients, IRR (incidence rate ratio) was 1.23 (95% CI 1.10-1.37). The use of parenteral MTX increased even more; IRR was 1.97 (95% CI 1.61-2.41). During the first 2 years of their disease, 18% of the first cohort received subcutaneous biologic agents, while the corresponding proportion in the last cohort was 31%. Biologic agents were more likely to be introduced for patients with early (3 months) MTX administration than for patients without early MTX introduction; HR (hazard ratio) 2.19 (95% CI 1.63-2.93). During the follow-up, MTX administration became more prevalent for the treatment of JIA soon after diagnosis, mostly because of the increase in the use of parenteral MTX.Key Points • The drug therapy for treating juvenile idiopathic arthritis has changed during recent years. • Methotrexate, some other conventional DMARDs, and biologic DMARDs are introduced earlier.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Juvenil/tratamento farmacológico , Artrite Juvenil/epidemiologia , Fatores Biológicos/uso terapêutico , Metotrexato/uso terapêutico , Adolescente , Criança , Pré-Escolar , Estudos de Coortes , Prescrições de Medicamentos/estatística & dados numéricos , Uso de Medicamentos/estatística & dados numéricos , Feminino , Finlândia/epidemiologia , Humanos , Masculino , Modelos de Riscos Proporcionais , Sistema de Registros
2.
Clin Rheumatol ; 39(1): 299, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31797167

RESUMO

The first and family names of the authors were interchanged and are now presented correctly. The original article has been corrected.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...